期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗胃癌的复方新药S-1的研究进展 被引量：8

暂未订购
导出
摘要 S-1是替加氟(tegafur,FT)、吉美拉西(gimeracil,CDHP)和奥替拉西钾(oteracilpotassium,OXO)复方制剂的商品名,各组成摩尔比为1∶0.4∶1。该药由日本太和药业首创开发,1999年在日本首次上市,主要适应证为胃癌和头颈部癌。FT在CDHP和OXO两种药物的调节作用下,增强了5-氟尿嘧啶(5-FU)的抗癌作用,降低了其毒副作用。国外临床试验表明,单药治疗晚期胃癌的总有效率达到44.6%,治疗结直肠癌的总有效率达35.5%,同时患者耐受性较好。目前,在日本S-1已成为治疗晚期胃肠道恶性肿瘤的一线药物。
作者 张晗
机构地区 北京中联华新国际医药科技有限公司
出处 《国外医学（药学分册）》 2005年第5期304-307,共4页 Foreign Medical Sciences(Section of Pharmarcy)
关键词 胃癌 抗癌药 S-1 替加氟 吉美拉西 奥替拉西钾
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献18

  • 1Sato A, Ito T, Tomita T, et al. Chemotherapy of gastric cancer-a review of clinical trials in Japan[J]. Gan To Kagaku Ryoho ,2002,29(9): 1522 - 1531.
  • 2Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents [J]. Curr Pharm Biotechnol, 2000, 1(2):137-164.
  • 3Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of5-fluorouracil (capecitabine, UFT, S-1): a review[J]. Oncologist, 2002, 7(4) :288 - 323.
  • 4Diaz-Canton E, Pazdur R. Preoperative combined oral UFT plus leucovorin and radiation therapy for rectal cancer[J]. Oncology(Williston Park), 1997, 11(9 Suppl 10):58-60.
  • 5Hoff PM. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential[J]. Invest New Drugs, 2000, 18(4) :331 - 342.
  • 6Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer[J]. Gastric Cancer, 2003, 6(Suppl 1) :71 - 81.
  • 7Yoshisue K, Hironaga K, Yamaguchi S, et al. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats[J]. Cancer Chemother Pharmacol, 2000, 46(1):51-56.
  • 8Yoshisue K, Masuda H, Matsushima E, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent ( drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats[J].Drug Metab Dispos, 2000, 28(10):1162- 1167.
  • 9Takechi T, Okabe H, Ikeda K, et al. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts[J]. Oncol Rep, 2005, 14(1):33- 39.
  • 10Hayashi T, Tanaka G, Irimura K, et al. Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP and Oxo[J]. J Toxicol Sci, 1996, 21(Suppl 3) :495 - 504.

同被引文献55

  • 1胡敏,胡昌勤,刘文英.LC/MS鉴定头孢菌素降解物结构[J].药物分析杂志,2005,25(3):369-373. 被引量：41
  • 2戚苏明,刘江华,曹燕锋,蔡伟,顾志兰.替吉奥胶囊处方优选[J].中国药业,2006,15(11):44-45. 被引量：3
  • 3秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量：269
  • 4Sato A, Ito T, Tomita T, et al. Chemotherapy of gastric cancer-a review of clinical trials in Japan [J]. Gan To Kagaku Ryoho, 2002, 29 (9): 1522.
  • 5Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents [J]. Curt Pharm Biotechnol, 2000, 1 (2): 137.
  • 6Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity of fluoropyrimidines by metabolic and target enzyme activities in gastric cancer [J]. Gastric Cancer, 2003, 6 (Suppl 1): 71.
  • 7Yoshisue K, Hironaga K, Yamaguchi S, et al. Reduction of 5- fluorouracil gastroiontestinal toxicity resulting from the prtection of thymidylate synthase in gastrointestinal tissue by repeated simultaneous administration of potassium oxonate in rats [J]. Cancer ChemotherPharmacol, 2000, 46 (1): 51.
  • 8Yoshisue K, Masuda H, Matsushima E, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent(drug combination of tegafur, 5- chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats[J]. Drug Metab Dispos, 2000,28 (10) : 1162.
  • 9CHU QS,HAMMOND LA,SCHWARTZG, etal. Phase Ⅰ and pharmacokinetic study of the oral fluoropyrimidine S-1 on a oncedaily - for - 28 - day schedule in patients with advanced malignancies [J]. Clin Cancer Res, 2004, 10 ( 15 ) : 4913 -4921.
  • 10SCHOFFSKI P. The modulated oral fluoropyrimidine prodrug S- 1 , and its use in gastrointestinal cancer and other solid tumors [ J ]. Anticancer Drugs ,2004,15 ( 2 ) :85 - 106.

引证文献8

二级引证文献34

国外医学（药学分册）
2005年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部